<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03595579</url>
  </required_header>
  <id_info>
    <org_study_id>AXS-05-MDD-201</org_study_id>
    <nct_id>NCT03595579</nct_id>
  </id_info>
  <brief_title>Assessing Symptomatic Clinical Episodes in Depression</brief_title>
  <acronym>ASCEND</acronym>
  <official_title>A Randomized, Double-Blind, Active-Controlled Trial of AXS-05 Administered Orally to Subjects With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axsome Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axsome Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, Double-Blind, Active-Controlled Study of AXS-05 for MDD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety and efficacy of AXS-05 in a randomized, double-blind,
      active-controlled study in patients diagnosed with major depressive disorder (MDD)
      experiencing an acute episode.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 30, 2018</start_date>
  <completion_date type="Actual">January 7, 2019</completion_date>
  <primary_completion_date type="Actual">January 7, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety outcomes: types and rates of adverse events; discontinuations due to adverse events.</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Montgomery and Asberg Depression Rating Scale (MADRS) for change in severity of symptoms.</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Global Impression of Severity of Illness (CGI-S) for change in severity of symptoms.</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Global Impression of Improvement of Illness (CGI-I) for change in improvement of disease state.</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quick Inventory of Depressive Symptomology - Self-Rated (QIDS-SR-16) for change in subject-rated depressive symptomology.</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>AXS-05</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupropion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AXS-05</intervention_name>
    <description>AXS-05 taken daily for 6 weeks.</description>
    <arm_group_label>AXS-05</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>Bupropion taken daily for 6 weeks.</description>
    <arm_group_label>Bupropion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Currently meets DSM-5 criteria for MDD

          -  Body mass index (BMI) between 18 and 40 kg/m^2, inclusive

          -  Agree to use adequate method of contraception for the duration of the study

          -  Additional criteria may apply

        Exclusion Criteria:

          -  Suicide risk

          -  History of treatment resistance in current depressive episode

          -  History of electroconvulsive therapy, vagus nerve stimulation, transcranial magnetic
             stimulation or any experimental central nervous system treatment during the current
             episode or in the past 6 months

          -  Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study

          -  Additional criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Axsome Study Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axsome Study Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axsome Study Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axsome Study Site</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.axsome.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>June 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2018</study_first_posted>
  <last_update_submitted>April 15, 2019</last_update_submitted>
  <last_update_submitted_qc>April 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AXS-05</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>MDD</keyword>
  <keyword>Axsome</keyword>
  <keyword>NMDA Receptor</keyword>
  <keyword>Depression</keyword>
  <keyword>Dextromethorphan</keyword>
  <keyword>Bupropion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>via publication</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

